← All trials
NCT05438407
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Jun 10, 2024
- Completion date
- Sep 12, 2024
- First posted
- Jun 30, 2022
- Last posted
- Jul 11, 2022
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharming GroupLead sponsor
- CMIC Co, Ltd. JapanCollaborator
- LabCorpCollaborator
- Aixial GroupCollaborator
- FortreaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.